Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

Van, Joanne T.; Pan, Jiehong; Wasty, Talat; Chan, Eve; Wu, Xiaoshan; Charles, M. Arthur

doi:10.1016/s0002-9149(02)02333-0

Cited by 51 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with hyperlipidemia or dyslipidemia, combination niacin extended release/simvastatin therapy resulted in greater favorable changes in size and number of HDL particle subclasses and distribution of HDL particle size compared with atorvastatin alone [211]. In diabetic subjects combination niacin and atorvastatin therapy improves the atherogenic lipid profile more effectively than monotherapy [212].…”

Section: Combination Therapiesmentioning

confidence: 99%

Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment

2013

View full text Add to dashboard Cite

■ AbstractType 2 diabetes (T2D) markedly increases the risk of cardiovascular disease. Endothelial dysfunction (ED), an early indicator of diabetic vascular disease, is common in T2D and independently predicts cardiovascular risk. Although the precise pathogenic mechanisms for ED in T2D remain unclear, at inception they probably involve uncoupling of both endothelial nitric oxide synthase activity and mitochondrial oxidative phosphorylation, as well as the activation of vascular nicotinamide adenine dinucleotide phosphate oxidase. The major contributing factors include dyslipoproteinemia, oxidative stress, and inflammation. Therapeutic interventions are designed to target these pathophysiological factors that underlie ED. Therapeutic interventions, including lifestyle changes, antiglycemic agents and lipid-regulating therapies, aim to correct hyperglycemia and atherogenic dyslipidemia and to improve ED. However, high residual cardiovascular risk is seen in both research and clinical practice settings. Well-designed studies of endothelial function in appropriately selected volunteers afford a good opportunity to test new therapeutic interventions, paving the way for clinical trials and utilization in the care of the diabetic patient. However, based on the results from a recent clinical trial, niacin should not be added to a statin in individuals with low high-density lipoprotein cholesterol and very well controlled low-density lipoprotein cholesterol.

show abstract

Section: Combination Therapiesmentioning

confidence: 99%

Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment

2013

View full text Add to dashboard Cite

show abstract

“…An elevated level of Lp(a) (> 30 mg/dl) has been identified as an independent and additional risk factor for premature atherosclerosis (43), although the effects on clinical outcomes of reducing levels of this lipoprotein have yet to be demonstrated in a randomised trial. Lipid subprofiles also improve after Niaspan Ò treatment, with increases in the size of LDL and HDL particles; again, such effects are believed to be antiatherogenic (44)(45)(46).…”

Section: Efficacy Of Niaspan âmentioning

confidence: 99%

Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®)

Vogt

Kassner

Hostalek

et al. 2007

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Statin/niacin combinations typically result in changes in LDL-C, HDL-C and triglycerides of -30 to -55%, +16 to +42% and -11 to -69%, respectively [56][57][58][59][60][61][62][63][64].…”

Section: Statins In Combination With Niacinmentioning

confidence: 99%